WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences | Cases

Search Results -

Terms	Documents
6248714.pn.	1

Database: US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L3

Refine Search

Recall Text | Clear

Search History

DATE: Thursday, January 30, 2003 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT; PLUR=YES; OP=ADJ			
L3	6248714.pn.	1	L3
L2	6214559.pn.	1	L2
L1	il 13 bc	2	L1

END OF SEARCH HISTORY

WEST

End of Result Set

Generate Collection Print

L3: Entry 1 of 1 File: USPT Jun 19, 2001

US-PAT-NO: 6248714
DOCUMENT-IDENTIFIER: US 6248714 B1

TITLE: Methods of inhibiting binding and treating Ig-mediated responses with IL-13 receptor

DATE-ISSUED: June 19, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Collins; Mary	Natick	MA		
Donaldson; Debra	Medford	MA		
Fitz; Lori	Arlington	MA		
Neben; Tamlyn	Acton	MA		
Whitters; Matthew	Hudson	MA		
Wood; Clive	Boston	MA		

US-CL-CURRENT: 514/2; 424/85.1, 435/7.1, 514/12, 514/8, 514/826, 514/885

CLAIMS:

What is claimed is:

1. A method of inhibiting binding of IL-13 to the IL-13 receptor in a mammalian subject, said method comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a protein and a pharmaceutically acceptable carrier, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:2;

(b) the amino acid sequence of SEQ ID NO:2 from amino acids 22 to 334;

(c) the amino acid sequence of SEQ ID NO:2 from amino acids 357 to 383;

(d) the amino acid sequence of SEQ ID NO:4;

(e) the amino acid sequence of SEQ ID NO:4 from amino acids 26 to 341; and

(f) the amino acid sequence of SEQ ID NO:4 from amino acids 363 to 380.

2. The method of claim 1 wherein said receptor chain protein comprises the amino acid sequence of SEQ ID NO:2.

3. The method of claim 1 wherein said receptor chain protein comprises the amino acid sequence of SEQ ID NO:2 from amino acids 22 to 334.

4. The method of claim 1 wherein said receptor chain protein comprises the amino acid sequence of SEQ ID NO:4.

5. The method of claim 1 wherein said receptor chain protein comprises the amino acid sequence of SEQ ID NO:4 from amino acids 26 to 341.

6. A method of treating an Ig-mediated condition in a mammalian subject, said method comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a proterin and a pharmaceutically acceptable carrier, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:2;

(b) the amino acid sequence of SEQ ID NO:2 from amino acids 22 to 334;

(c) the amino acid sequence of SEQ ID NO:2 from amino acids 357 to 383;

(d) the amino acid sequence of SEQ ID NO:4;

(e) the amino acid sequence of SEQ ID NO:4 from amino acids 26 to 341;

(f) the amino acid sequence of SEQ ID NO:4 from amino acids 363 to 380; and

(g) fragments of (a)-(f) having the ability to bind IL-13 or a biologically active fragment thereof.

7. The method of claim 6 wherein said condition is an IgE-mediated condition.

8. The method of claim 7 wherein said condition is selected from the group consisting of an allergic condition, asthma and an immune complex disease.

9. The method of claim 8 wherein said condition is selected from the group consisting of lupus, nephritis, thyroiditis and Grave's disease.

10. The method of claim 6 wherein said protein comprises the amino acid sequence of SEQ ID NO:2.

11. The method of claim 6 wherein said protein comprises the amino acid sequence of SEQ ID NO:2 from amino acids 22 to 334.

12. The method of claim 6 wherein said protein comprises the amino acid sequence by of SEQ ID NO:2 from amino acids 357 to 383.

13. The method of claime 6 wherein said protein comprises the amino acid sequence of SEQ ID NO:4.

14. The method of claim 6 wherein said protein comprises the amino acid sequence of SEQ ID NO:4 from amino acids 26 to 341.

15. The method of claim 6 wherein said protein comprises the amino acid sequence of SEQ ID NO:4 from amino acids 363 to 380.

WEST

End of Result Set

Generate Collection Print

L1: Entry 2 of 2 File: USPT Jan 20, 1998

US-PAT-NO: 5710023
DOCUMENT-IDENTIFIER: US 5710023 A

TITLE: IL-13 cytokine receptor chain

DATE-ISSUED: January 20, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Collins; Mary	Natick	MA		
Donaldson; Debra	Medford	MA		
Fitz; Lori	Arlington	MA		
Neben; Tamlyn	Acton	MA		
Whitters; Matthew	Hudson	MA		
Wood; Clive	Boston	MA		

US-CL-CURRENT: 435/69.1; 435/253.5, 435/320.1, 435/325, 530/350, 536/23.5

CLAIMS:

What is claimed is:

1. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:1 from nucleotide 256 to nucleotide 1404;

(b) the nucleotide sequence of SEQ ID NO:3 from nucleotide 103 to nucleotide 1242;

(c) a nucleotide sequence encoding the IL-13R binding chain varying from the sequence of the nucleotide sequence specified in (a) or (b) as a result of degeneracy of the genetic code;

(d) a nucleotide sequence capable of hybridizing under conditions comprising hybridization at 52.degree. C. in 5.times.SSC followed by washing at 52.degree. C. in 2.times.SSC to the nucleotide specified in (a) or (b);

(e) a nucleotide sequence encoding a species homologue of the sequence specified in (a) or (b); and

(f) an allelic variant of the nucleotide sequence specified in (a) or (b).

2. The polynucleotide of claim 1 wherein said nucleotide sequence encodes

for a protein having a biological activity of the IL-13R binding chain.

3. The polynucleotide of claim 1 wherein said nucleotide sequence is operably linked to an expression control sequence.

4. The polynucleotide of claim 1 comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 319 to nucleotide 1257.

5. The polynucleotide of claim 1 comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 1324 to nucleotide 1404.

6. The polynucleotide of claim 1 comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 178 to nucleotide 1125.

7. The polynucleotide of claim 1 comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 1189 to nucleotide 1242.

8. A host cell transformed with the polynucleotide of claim 3.

9. The host cell of claim 8, wherein said cell is a mammalian cell.

10. A process for producing a IL-13bc protein, said process comprising:

(a) growing a culture of the host cell of claim 8 in a suitable culture medium; and

(b) purifying the IL-13bc protein from the culture.

11. An isolated polynucleotide comprising a nucleotide sequence encoding a peptide or protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:2;

(b) the amino acid sequence of SEQ ID NO:2 from amino acids 22 to 334;

(c) the amino acid sequence of SEQ ID NO:2 from amino acids 357 to 383;

(d) the amino acid sequence of SEQ ID NO:4;

(e) the amino acid sequence of SEQ ID NO:4 from amino acids 26 to 341;

(f) the amino acid sequence of SEQ ID NO:4 from amino acids 363 to 380; and

(g) fragments of (a)-(f) having a biological activity of the IL-13 receptor binding chain.

12. The polynucleotide of claim 11 encoding a peptide or protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids 1 to 331.

13. The polynucleotide of claim 11 encoding a peptide or protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids 26 to 331.

14. The polynucleotide of claim 11 encoding a peptide or protein comprising the amino acid sequence of SEQ ID NO:2.

15. The polynucleotide of claim 11 encoding a peptide or protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids 22 to 334.

16. The polynucleotide of claim 11 encoding a peptide or protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids 357 to 383.

WEST

Generate Collection Print

L1: Entry 1 of 2 File: USPT Jul 31, 2001

US-PAT-NO: 6268480
DOCUMENT-IDENTIFIER: US 6268480 B1

TITLE: IL-13 Receptor chain

DATE-ISSUED: July 31, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Collins; Mary	Natick	MA		
Donaldson; Debra	Medford	MA		
Fitz; Lori	Arlington	MA		
Neben; Tamlyn	Acton	MA		
Whitters; Matthew	Hudson	MA		
Wood; Clive	Boston	MA		

US-CL-CURRENT: 530/350; 530/351

CLAIMS:

What is claimed is:

1. An isolated IL-13bc protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO: 2;

(b) the amino acid sequence of SEQ ID NO: 2 from amino acids 22 to 334;

(c) the amino acid sequence of SEQ ID NO: 2 from amino acids 357 to 383;

(d) the amino acid sequence of SEQ ID NO: 4;

(e) the amino acid sequence of SEQ ID NO: 4 from amino acids 26 to 341;

(f) the amino acid sequence of SEQ ID NO: 4 from amino acids 363 to 380; and

(g) fragments of (a)-(f) having the ability to bind IL-13 or a biologically active fragment thereof.

2. The protein of claim 1 comprising the amino acid sequence of SEQ ID NO: 2.

3. The protein of claim 1 comprising the sequence from amino acid 22 to 334 of SEQ ID NO: 2.

4. The protein of claim 1 comprising the amino acid sequence of SEQ ID NO:

4.

5. The protein of claim 1 comprising the sequence from amino acid 26 to 341 of SEQ ID NO: 4.

6. A pharmaceutical composition comprising a protein of claim 1 and a pharmaceutically acceptable carrier.

7. The protein of claim 1 comprising the amino acid sequence of SEQ ID NO: 2 from amino acids 1 to 331.

8. The protein of claim 1 comprising the amino acid sequence of SEQ ID NO: 2 from amino acids 26 to 331.

9. The protein of claim 1 comprising the amino acid sequence of SEQ ID NO: 2 from amino acids 357 to 383.

10. The protein of claim 1 comprising the amino acid sequence of SEQ ID NO: 4 from amino acids 363 to 380.

11. The protein of claim 1 wherein said amino acid sequence is part of a fusion protein.

12. The protein of claim 11 comprising an Fc fragment.

13. A protein produced according to a process comprising:

(a) growing a culture of a host cell of in a suitable culture medium; and

(b) purifying the protein from the culture,

wherein said host cell is transformed with a polynucleotide operably linked to an expression control sequence, and wherein said polynucleotide comprises a nucleotide sequence selected from the group consisting of:

(1) the nucleotide sequence of SEQ ID NO: 1 from nucleotide 256 to nucleotide 1404;

(2) the nucleotide sequence of SEQ ID NO: 3 from nucleotide 103 to nucleotide 1242;

(3) a nucleotide sequence encoding the IL-13R binding chain varying from the sequence of the nucleotide sequence specified in (1) or (2) as a result of degeneracy of the genetic code;

(4) a nucleotide sequence capable of hybridizing under conditions comprising hybridization at 52.degree. C. in 5.times.SSC followed by washing at 52.degree. C. in 2.times.SSC to the nucleotide specified in (1) or (2); and

(5) an allelic variant of the nucleotide sequence specified in (1) or (2).

14. The protein of claim 13 wherein said polynucleotide comprises the nucleotide sequence of SEQ ID NO: 1 from nucleotide 256 to nucleotide 1404.

15. The protein of claim 13 wherein said polynucleotide comprises the nucleotide sequence of SEQ ID NO: 3 from nucleotide 103 to nucleotide 1242.

WEST

End of Result Set

Generate Collection Print

L2: Entry 1 of 1 File: USPT Apr 10, 2001

US-PAT-NO: 6214559
DOCUMENT-IDENTIFIER: US 6214559 B1

TITLE: Methods of identifying inhibitors of binding of IL-13 to the IL-13 receptor chain

DATE-ISSUED: April 10, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Collins; Mary	Natick	MA		
Donaldson; Debra	Medford	MA		
Fitz; Lori	Arlington	MA		
Neben; Tamlyn	Acton	MA		
Whitters; Matthew	Hudson	MA		
Wood; Clive	Boston	MA		

US-CL-CURRENT: 435/7.1; 435/69.1, 435/7.2, 435/7.8

CLAIMS:

What is claimed is:

1. A method of identifying an inhibitor of IL-13 binding to the IL-13 receptor which comprises:

(a) combining a receptor chain protein with IL-13 or a biologically active fragment thereof, said combination forming a first binding mixture;

(b) measuring the amount of binding between the receptor chain protein and the IL-13 or fragment in the first binding mixture;

(c) combining a compound with the receptor chain protein and the IL-13 or fragment to form a second binding mixture;

(d) measuring the amount of binding in the second binding mixture; and

(e) comparing the amount of binding in the first binding mixture with the amount of binding in the second binding mixture;

wherein the compound is capable of inhibiting IL-13 binding to the IL-13 receptor when a decrease in the amount of binding of the second binding mixture occurs, and wherein said receptor chain protein comprises an amino acid sequence selected from the group consisting of:

(1) the amino acid sequence of SEQ ID NO:2;

(2) the amino acid sequence of SEQ ID NO:2 from amino acids 22 to 334;

(3) the amino acid sequence of SEQ ID NO:2 from amino acids 357 to 383;

(4) the amino acid sequence of SEQ ID NO:4;

(5) the amino acid sequence of SEQ ID NO:4 from amino acids 26 to 341; and

(6) the amino acid sequence of SEQ ID NO:4 from amino acids 363 to 380.

2. The method of claim 1 wherein said protein comprises the amino acid sequence of SEQ ID NO:2.

3. The method of claim 1 wherein said protein comprises the amino acid sequence of SEQ ID NO:2 from amino acids 22 to 334.

4. The method of claim 1 wherein said protein comprises the amino acid sequence of SEQ ID NO:4.

5. The method of claim 1 wherein said protein comprises the amino acid sequence of SEQ ID NO:4 from amino acids 26 to 341.